|
| Xiao Chai Hu Tang for Liver Diseases: A Literature Review |
| |
| View Full Text View/Add Comment Download reader |
| DOI：10.4103/wjtcm.wjtcm_4_17 |
| KeyWord:Hepatic fibrosis, hepatitis, hepatoma, interstitial pneumonia, tolbutamide, Xiao Chai Hu Tang (minor bupleurum decoction) |
| Author | Institution |
| Yi Wanga |
a.Department of Gastroenterology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine |
| Li Lia |
b.Clinical Research Institute of Integrated Traditional Chinese and Western Medicine, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine,
Shanghai University of Traditional Chinese Medicine, Shanghai , China |
| Yan‑Mei Chenga |
a.Department of Gastroenterology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine |
| Sheng‑Liang Zhua |
a.Department of Gastroenterology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine |
|
| Hits: 1914 |
| Download times: 2524 |
| Abstract: |
| The objective of this study is to summarize the pharmacological effects and the mechanisms of action of Xiao Chai Hu Tang (XCHT, Minor
Bupleurum Decoction) on liver diseases, so as to give relevant researchers a valuable insight and benefit patients with hepatopathy. PubMed
was used to search for and collect scientific publications related to XCHT and liver diseases from 1986 to 2016. The available scientific
results or evidence were read, classified, and analyzed. XCHT showed clinical efficacy in patients with hepatic diseases including hepatitis,
hepatic fibrosis, and hepatoma. The mechanisms involved the production of cytokines, the regulation of immune function, the suppression
of lipid peroxidation, etc., XCHT might work on the metabolism of some medications such as tolbutamide by the regulation of gastric
emptying and intragastric pH. XCHT exhibited a very low toxicity profile, such as interstitial pneumonia due to duration of medication,
patients’ age, and drug combination. XCHT has been a eutherapeutic supplemental remedy for liver diseases. However, many mechanisms
of action and effects of XCHT on new types of liver diseases still remain unclear, so more and more animal experiments and human clinical
trials are needed to obtain enough proofs for the clinical use of XCHT in new types of hepatosis such as nonalcoholic fatty liver disease
and autoimmune liver disease |
| Close |
|
|
|